Liestal, Switzerland, May 2, 2017 - Santhera Pharmaceuticals (SIX: SANN) announces that it has signed an agreement with Pharmathen to market Raxone ® for the treatment of Leber's hereditary optic neuropathy (LHON) in Greece and Cyprus. LHON is a rare ...
 |
| READ THE ORIGINAL POST AT inpublic.globenewswire.com |